NCT04513509

Brief Summary

To search for the best marker for the patients in atrial fibrillation with rate control

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
13

participants targeted

Target at below P25 for not_applicable atrial-fibrillation

Timeline
Completed

Started Oct 2020

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 9, 2020

Completed
5 days until next milestone

First Posted

Study publicly available on registry

August 14, 2020

Completed
2 months until next milestone

Study Start

First participant enrolled

October 21, 2020

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 21, 2022

Completed
10 days until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2022

Completed
Last Updated

January 16, 2026

Status Verified

January 1, 2026

Enrollment Period

1.7 years

First QC Date

August 9, 2020

Last Update Submit

January 15, 2026

Conditions

Atrial FibrillationRate ControlCardiopulmonary Exercise Test

Keywords

Atrial Fibrillationrate controlcardiopulmonary exercise test

Outcome Measures

Primary Outcomes (1)

  • Change of Maximal Oxygen consumption

    acquire the data by Cardiopulmonary exercise test (CPET) with different (low and high) drug dosages for rate control

    0, 3, 6 months

Study Arms (1)

rate control

EXPERIMENTAL
Drug: Atenolol, Bisoprolol, Metoprolol, Nebivolol, Propranolol, Diltiazem, Verapamil, digoxin

Interventions

Atenolol, Bisoprolol, Metoprolol, Nebivolol, Propranolol, Diltiazem, Verapamil, digoxinDRUG

Start with empirical lower dose for 3 months, and then titrate up

rate control

Eligibility Criteria

Age18 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • \~90 years old
  • Rate control is preferred after shared decision making

You may not qualify if:

  • cannot cooperate with or complete CPET
  • has contraindication for CPET, such as uncontrolled heart failure, hypertension, angina, valvular heart disease, lung function impariment that SaO2\<90% at room air.
  • Ventricular rate below 80/min before any medication
  • Permanent pacemaker implanted

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Taiwan University Hospital

Taipei, Taiwan

Location

MeSH Terms

Conditions

Atrial Fibrillation

Interventions

AtenololBisoprololMetoprololNebivololPropranololDiltiazemVerapamilDigoxin

Condition Hierarchy (Ancestors)

Arrhythmias, CardiacHeart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

PhenoxypropanolaminesPropanolaminesAmino AlcoholsAlcoholsOrganic ChemicalsPropanolsAminesEthanolaminesBenzopyransPyransHeterocyclic Compounds, 1-RingHeterocyclic CompoundsHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingNaphthalenesPolycyclic Aromatic HydrocarbonsHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsPolycyclic CompoundsBenzazepinesPhenethylaminesEthylaminesDigitalis GlycosidesCardenolidesCardiac GlycosidesCardanolidesSteroidsFused-Ring CompoundsGlycosidesCarbohydrates

Study Officials

  • Chih-Chieh Yu, MD.PhD

    National Taiwan University Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SEQUENTIAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 9, 2020

First Posted

August 14, 2020

Study Start

October 21, 2020

Primary Completion

June 21, 2022

Study Completion

July 1, 2022

Last Updated

January 16, 2026

Record last verified: 2026-01

Locations

TW(1)